Technical Analysis for TCRX - TScan Therapeutics, Inc.

Grade Last Price % Change Price Change
B 10.0 1.63% 0.16
TCRX closed up 1.63 percent on Monday, August 2, 2021, on 1.36 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical TCRX trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 1.63%
Multiple of Ten Bearish Other 1.63%
Hot IPO Pullback Bullish Swing Setup 3.52%
NR7 Range Contraction 3.52%
NR7-2 Range Contraction 3.52%
Inside Day Range Contraction 3.52%
Hot IPO Pullback Bullish Swing Setup 4.17%
NR7 Range Contraction 4.17%
Multiple of Ten Bearish Other 4.06%
Multiple of Ten Bullish Other -0.40%
Older End-of-Day Signals for TCRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Sector: Other
Industry: Other
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer

Is TCRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 12.32
52 Week Low 9.1
Average Volume 75,481
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 9.76
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs) N/A
Chandelier Exit (Short, 3 ATRs) N/A
Upper Bollinger Bands 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.72
Resistance 3 (R3) 10.71 10.45 10.60
Resistance 2 (R2) 10.45 10.27 10.46 10.56
Resistance 1 (R1) 10.23 10.16 10.34 10.24 10.52
Pivot Point 9.97 9.97 10.03 9.98 9.97
Support 1 (S1) 9.75 9.79 9.86 9.76 9.48
Support 2 (S2) 9.49 9.68 9.50 9.44
Support 3 (S3) 9.27 9.49 9.40
Support 4 (S4) 9.28